Biomarker analysis in the phase 3 CLEAR trial shows biomarkers don't impact the superiority of lenvatinib plus pembrolizumab versus sunitinib as a first-line therapy in patients diagnosed with advanced kidney cancer.
Dana-Farber's Toni Choueiri, MD, presents at #ASCO24. Video published 6/7/2024